ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10486254" target="_blank" >RIV/00064165:_____/24:10486254 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10486254
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=EO0CzYfwbJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=EO0CzYfwbJ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/ijgc-2024-005823" target="_blank" >10.1136/ijgc-2024-005823</a>
Alternative languages
Result language
angličtina
Original language name
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
Original language description
A collaboration was established between the European Society of Gynaecological Oncology (ESGO), the European Reference Network on Rare Adult Solid Cancers (EURACAN), and the Gynecologic Cancer InterGroup (GCIG) with the aim of developing clinically relevant, evidence-based consensus guidelines on the management of patients with uterine sarcomas from diagnosis to relapse. ESGO/EURACAN/GCIG nominated practicing clinicians from centers of expertise in the management of patients with uterine sarcomas to serve on the expert panel (25 experts). To ensure that the statements were evidence-based, data identified from a systematic search were reviewed and critically appraised. In the absence of robust scientific evidence, clinical recommendations were based on the consensus of the international development group. Prior to publication, the guidelines were reviewed by 104 independent international clinicians with expertise in uterine sarcomas. Attention was given to imaging, pathology, and molecular analyses in addition to clinical management. Recommendations for surgery, including specific recommendations at initial diagnosis and at relapse, were developed. Indications for radiation and systemic therapies, including chemotherapy options, endocrine therapies, and targeted therapies, were addressed for the following histological subgroups of uterine sarcomas: high-grade endometrial stromal sarcomas, undifferentiated sarcomas, low-grade endometrial stromal sarcomas, uterine leiomyosarcomas, adenosarcomas, and selected very rare entities. Recommendations for follow-up and highlighted issues and unmet needs faced by long-term survivors were also discussed.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30214 - Obstetrics and gynaecology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Gynecological Cancer
ISSN
1048-891X
e-ISSN
1525-1438
Volume of the periodical
34
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
23
Pages from-to
1499-1521
UT code for WoS article
001320479700001
EID of the result in the Scopus database
2-s2.0-85206017175